Equities research analysts forecast that Exelixis, Inc. (NASDAQ:EXEL) will report earnings of $0.12 per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Exelixis’ earnings. The highest EPS estimate is $0.17 and the lowest is $0.08. Exelixis also posted earnings of $0.12 per share during the same quarter last year. The firm is expected to announce its next quarterly earnings report after the market closes on Monday, February 26th.
According to Zacks, analysts expect that Exelixis will report full-year earnings of $0.49 per share for the current year, with EPS estimates ranging from $0.45 to $0.51. For the next financial year, analysts anticipate that the company will post earnings of $0.77 per share, with EPS estimates ranging from $0.53 to $1.24. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Exelixis.
EXEL has been the topic of several recent research reports. BidaskClub raised Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective on the stock in a research report on Tuesday, January 2nd. TheStreet raised Exelixis from a “c+” rating to a “b-” rating in a research report on Wednesday, October 18th. SunTrust Banks reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Exelixis in a research report on Thursday, December 21st. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Exelixis in a research report on Tuesday, December 19th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $32.13.
In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the sale, the director now owns 64,829 shares in the company, valued at approximately $1,964,318.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. grew its position in shares of Exelixis by 18.8% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 31,612 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 5,005 shares in the last quarter. Teachers Advisors LLC grew its position in Exelixis by 17.7% in the fourth quarter. Teachers Advisors LLC now owns 364,514 shares of the biotechnology company’s stock worth $11,081,000 after acquiring an additional 54,689 shares in the last quarter. Paloma Partners Management Co purchased a new position in Exelixis in the fourth quarter worth about $330,000. Raymond James & Associates grew its position in Exelixis by 178.8% in the fourth quarter. Raymond James & Associates now owns 80,197 shares of the biotechnology company’s stock worth $2,438,000 after acquiring an additional 51,431 shares in the last quarter. Finally, Ardsley Advisory Partners purchased a new position in Exelixis in the fourth quarter worth about $380,000. Hedge funds and other institutional investors own 81.43% of the company’s stock.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.